BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kleeff J, Reiser C, Hinz U, Bachmann J, Debus J, Jaeger D, Friess H, Büchler MW. Surgery for recurrent pancreatic ductal adenocarcinoma. Ann Surg. 2007;245:566-572. [PMID: 17414605 DOI: 10.1097/01.sla.0000245845.06772.7d] [Cited by in Crossref: 164] [Cited by in F6Publishing: 149] [Article Influence: 10.9] [Reference Citation Analysis]
Number Citing Articles
1 Dewitt J, Sherman S, Al-haddad M, Mchenry L, Cote GA, Leblanc JK. EUS-guided FNA of local recurrence of pancreatic cancer after surgical resection. Gastrointestinal Endoscopy 2010;72:1076-80. [DOI: 10.1016/j.gie.2010.07.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Eskander MF, Bliss LA, Tseng JF. Pancreatic adenocarcinoma. Current Problems in Surgery 2016;53:107-54. [DOI: 10.1067/j.cpsurg.2016.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
3 Li D, Yang M, Liang M, Mei C, Lin Y, Yang F, Xiao Y, Chen Y, Wang F, Mao J, Su Z. c-Met-targeted near-infrared fluorescent probe for real-time depiction and dissection of perineural invasion and lymph node metastasis lesions in pancreatic ductal adenocarcinoma xenograft models. Biomater Sci 2021. [PMID: 34254599 DOI: 10.1039/d1bm00674f] [Reference Citation Analysis]
4 Zacharias T, Oussoultzoglou E, Jaeck D, Pessaux P, Bachellier P. Surgery for recurrence of periampullary malignancies. J Gastrointest Surg. 2009;13:760-767. [PMID: 19050979 DOI: 10.1007/s11605-008-0769-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
5 Fiorino S, Lorenzini S, Masetti M, Deleonardi G, Grondona AG, Silvestri T, Chili E, Del Prete P, Bacchi-Reggiani L, Cuppini A. Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma. Med Hypotheses. 2012;79:678-697. [PMID: 22959312 DOI: 10.1016/j.mehy.2012.08.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
6 van der Sijde F, Vietsch EE, Mustafa DAM, Li Y, van Eijck CHJ. Serum miR-338-3p and miR-199b-5p are associated with the absolute neutrophil count in patients with resectable pancreatic cancer. Clin Chim Acta 2020;505:183-9. [PMID: 32145274 DOI: 10.1016/j.cca.2020.03.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Sperti C, Moletta L, Merigliano S. Multimodality treatment of recurrent pancreatic cancer: Mith or reality? World J Gastrointest Oncol 2015; 7(12): 375-382 [PMID: 26689800 DOI: 10.4251/wjgo.v7.i12.375] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
8 Liu S, Qin Z, Xu J, Zeng J, Chen J, Niu L, Xu M. Irreversible electroporation combined with chemotherapy for unresectable pancreatic carcinoma: a prospective cohort study. Onco Targets Ther. 2019;12:1341-1350. [PMID: 30863100 DOI: 10.2147/ott.s186721] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
9 D'Haese JG, Renz BW, Ilmer M, Werner J. [Surgery for isolated local recurrence and metachronous oligometastasis in pancreatic cancer]. Chirurg 2020;91:628-35. [PMID: 32424598 DOI: 10.1007/s00104-020-01190-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Gouma DJ, Busch OR, van Gulik TM. Treatment of Pancreatic Adenocarcinoma: A European Perspective. Surgical Oncology Clinics of North America 2008;17:569-86. [DOI: 10.1016/j.soc.2008.02.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Serafini S, Sperti C, Friziero A, Brazzale AR, Buratin A, Ponzoni A, Moletta L. Systematic Review and Meta-Analysis of Surgical Treatment for Isolated Local Recurrence of Pancreatic Cancer. Cancers (Basel) 2021;13:1277. [PMID: 33805716 DOI: 10.3390/cancers13061277] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Miyazaki M, Yoshitomi H, Shimizu H, Ohtsuka M, Yoshidome H, Furukawa K, Takayasiki T, Kuboki S, Okamura D, Suzuki D. Repeat pancreatectomy for pancreatic ductal cancer recurrence in the remnant pancreas after initial pancreatectomy: is it worthwhile? Surgery. 2014;155:58-66. [PMID: 24238124 DOI: 10.1016/j.surg.2013.06.050] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 8.1] [Reference Citation Analysis]
13 Hou YC, Chao YJ, Hsieh MH, Tung HL, Wang HC, Shan YS. Low CD8⁺ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44⁺/CD133⁺ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. Cancers (Basel) 2019;11:E541. [PMID: 30991694 DOI: 10.3390/cancers11040541] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
14 Müller SA, Tarantino I, Martin DJ, Schmied BM. Pancreatic surgery: beyond the traditional limits. Recent Results Cancer Res 2012;196:53-64. [PMID: 23129366 DOI: 10.1007/978-3-642-31629-6_4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
15 Hashimoto D, Chikamoto A, Ohmuraya M, Sakata K, Miyake K, Kuroki H, Watanabe M, Beppu T, Hirota M, Baba H. Pancreatic cancer in the remnant pancreas following primary pancreatic resection. Surg Today 2014;44:1313-20. [PMID: 23975591 DOI: 10.1007/s00595-013-0708-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
16 Huang H, Zou Y, Zhang H, Li X, Li Y, Deng X, Sun H, Guo Z, Ao L. A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma. Transl Res 2020;219:30-44. [PMID: 32119844 DOI: 10.1016/j.trsl.2020.02.004] [Reference Citation Analysis]
17 Schlitter AM, Esposito I. Definition of microscopic tumor clearance (r0) in pancreatic cancer resections. Cancers (Basel). 2010;2:2001-2010. [PMID: 24281214 DOI: 10.3390/cancers2042001] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
18 Zanini N, Lombardi R, Masetti M, Giordano M, Landolfo G, Jovine E. Surgery for isolated liver metastases from pancreatic cancer. Updates Surg. 2015;67:19-25. [PMID: 25702263 DOI: 10.1007/s13304-015-0283-6] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.9] [Reference Citation Analysis]
19 Luu AM, Belyaev O, Höhn P, Praktiknjo M, Janot M, Uhl W, Braumann C. Late recurrences of pancreatic cancer in patients with long-term survival after pancreaticoduodenectomy. J Gastrointest Oncol 2021;12:474-83. [PMID: 34012641 DOI: 10.21037/jgo-20-433] [Reference Citation Analysis]
20 Janot MS, Kersting S, Belyaev O, Matuschek A, Chromik AM, Suelberg D, Uhl W, Tannapfel A, Bergmann U. Can the new RCP R0/R1 classification predict the clinical outcome in ductal adenocarcinoma of the pancreatic head? Langenbecks Arch Surg. 2012;397:917-925. [PMID: 22695970 DOI: 10.1007/s00423-012-0953-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
21 Ishida J, Toyama H, Matsumoto I, Asari S, Goto T, Terai S, Nanno Y, Yamashita A, Mizumoto T, Ueda Y, Kido M, Ajiki T, Fukumoto T, Ku Y. Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: High cumulative incidence rates at 5 years after pancreatectomy. Pancreatology 2016;16:615-20. [DOI: 10.1016/j.pan.2016.05.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
22 Qin C, Yang G, Yang J, Ren B, Wang H, Chen G, Zhao F, You L, Wang W, Zhao Y. Metabolism of pancreatic cancer: paving the way to better anticancer strategies. Mol Cancer 2020;19:50. [PMID: 32122374 DOI: 10.1186/s12943-020-01169-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
23 Paik KY, Choi SH, Heo JS, Choi DW. Analysis of liver metastasis after resection for pancreatic ductal adenocarcinoma. World J Gastrointest Oncol 2012; 4(5): 109-114 [PMID: 22645634 DOI: 10.4251/wjgo.v4.i5.109] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
24 Dagoglu N, Callery M, Moser J, Tseng J, Kent T, Bullock A, Miksad R, Mancias JD, Mahadevan A. Stereotactic Body Radiotherapy (SBRT) Reirradiation for Recurrent Pancreas Cancer. J Cancer 2016;7:283-8. [PMID: 26918041 DOI: 10.7150/jca.13295] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
25 Imai K, Karasaki H, Ono Y, Sasajima J, Chiba S, Funakoshi H, Muraki M, Hanaoka H, Furukawa T, Furukawa H, Kono T, Nagashima K, Mizukami Y. Metachronous pancreatic cancer originating from disseminated founder pancreatic intraductal neoplasias (PanINs). J Pathol Clin Res 2015;1:76-82. [PMID: 27499895 DOI: 10.1002/cjp2.8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
26 Byrne JD, Jajja MRN, O'Neill AT, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ. Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer. Cancer Chemother Pharmacol 2018;81:991-8. [PMID: 29603014 DOI: 10.1007/s00280-018-3570-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
27 Liu J, Zhu C, Zhang L, Lu H, Wang Z, Lv J, Fan C. MicroRNA-1469-5p promotes the invasion and proliferation of pancreatic cancer cells via direct regulating the NDRG1/NF-κB/E-cadherin axis. Hum Cell 2020;33:1176-85. [PMID: 32757096 DOI: 10.1007/s13577-020-00399-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
28 Cogoi S, Jakobsen U, Pedersen EB, Vogel S, Xodo LE. Lipid-modified G4-decoy oligonucleotide anchored to nanoparticles: delivery and bioactivity in pancreatic cancer cells. Sci Rep 2016;6:38468. [PMID: 27929127 DOI: 10.1038/srep38468] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
29 Morimoto D, Yamada S, Sonohara F, Takami H, Hayashi M, Kanda M, Tanaka C, Kobayashi D, Nakayama G, Koike M, Fujiwara M, Fujii T, Kodera Y. Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. Pancreas 2020;49:699-705. [PMID: 32433409 DOI: 10.1097/MPA.0000000000001559] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
30 Lin M, Alnaggar M, Liang S, Shi J, Niu L, Chen J, Xu K. Using circulating tumor cells to evaluate the efficacy of irreversible electroporation for unresectasble pancreatic cancer. Immunol Res 2018;66:172-8. [DOI: 10.1007/s12026-017-8959-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
31 Shin SH, Kim HJ, Hwang DW, Lee JH, Song KB, Jun E, Shim IK, Hong SM, Kim HJ, Park KM, Lee YJ, Kim SC. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study. Oncotarget 2017;8:17945-59. [PMID: 28160547 DOI: 10.18632/oncotarget.14901] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 4.4] [Reference Citation Analysis]
32 Zeng XL, Wang HH, Meng MB, Wu ZQ, Song YC, Zhuang HQ, Qian D, Li FT, Zhao LJ, Yuan ZY, Wang P. Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump. Onco Targets Ther 2016;9:3985-92. [PMID: 27418841 DOI: 10.2147/OTT.S102784] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
33 Zhu X, Li F, Ju X, Shen Y, Cao Y, Cao F, Fang F, Qing S, Jia Z, Zhang H. Prediction of overall survival after re-irradiation with stereotactic body radiation therapy for pancreatic cancer with a novel prognostic model (the SCAD score). Radiother Oncol 2018;129:313-8. [PMID: 30217337 DOI: 10.1016/j.radonc.2018.08.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
34 Fujita Y, Kitago M, Masugi Y, Itano O, Shinoda M, Abe Y, Hibi T, Yagi H, Fujii-Nishimura Y, Sakamoto M, Kitagawa Y. Two cases of pancreatic ductal adenocarcinoma with intrapancreatic metastasis. World J Gastroenterol 2016; 22(41): 9222-9228 [PMID: 27895409 DOI: 10.3748/wjg.v22.i41.9222] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
35 Holm M, Saraswat M, Joenväärä S, Seppänen H, Renkonen R, Haglund C. Label-free proteomics reveals serum proteins whose levels differ between pancreatic ductal adenocarcinoma patients with short or long survival. Tumour Biol 2020;42:1010428320936410. [PMID: 32586207 DOI: 10.1177/1010428320936410] [Reference Citation Analysis]
36 Loos M, Kleeff J, Friess H, Büchler MW. Surgical Treatment of Pancreatic Cancer. Annals of the New York Academy of Sciences 2008;1138:169-80. [DOI: 10.1196/annals.1414.024] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 4.4] [Reference Citation Analysis]
37 Nakayama Y, Sugimoto M, Gotohda N, Konishi M, Takahashi S. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas. Journal of Surgical Research 2018;221:15-23. [DOI: 10.1016/j.jss.2017.07.016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
38 Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA. State-of-the-art PET/CT of the pancreas: current role and emerging indications. Radiographics. 2012;32:1133-1358; discussion 1358-1360. [PMID: 22786999 DOI: 10.1148/rg.324115143] [Cited by in Crossref: 62] [Cited by in F6Publishing: 48] [Article Influence: 6.2] [Reference Citation Analysis]
39 Loos M, Friess H, Kleeff J. Chirurgie maligner Pankreastumoren. Radiologe 2009;49:137-43. [DOI: 10.1007/s00117-008-1752-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
40 Charalambous P, Moris D, Karachaliou GS, Papalampros A, Dimitrokallis N, Tsilimigras DI, Oikonomou D, Petrou A. The efficacy and safety of the open approach irreversible electroporation in the treatment of pancreatic cancer: A systematic review. Eur J Surg Oncol 2020;46:1565-72. [PMID: 32536525 DOI: 10.1016/j.ejso.2020.05.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
41 Yamada S, Kobayashi A, Nakamori S, Baba H, Yamamoto M, Yamaue H, Fujii T. Resection for recurrent pancreatic cancer in the remnant pancreas after pancreatectomy is clinically promising: Results of a project study for pancreatic surgery by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. Surgery 2018;164:1049-56. [PMID: 30068484 DOI: 10.1016/j.surg.2018.05.050] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
42 Shima Y, Okabayashi T, Kozuki A, Sumiyoshi T, Tokumaru T, Saisaka Y, Date K, Iwata J. Completion pancreatectomy for recurrent pancreatic cancer in the remnant pancreas: report of six cases and a review of the literature. Langenbecks Arch Surg 2015;400:973-8. [DOI: 10.1007/s00423-015-1355-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
43 Kim HS, Kim YJ, Kim KG, Park JS. Preoperative CT texture features predict prognosis after curative resection in pancreatic cancer. Sci Rep. 2019;9:17389. [PMID: 31757989 DOI: 10.1038/s41598-019-53831-w] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
44 Ferrara B, Pignatelli C, Cossutta M, Citro A, Courty J, Piemonti L. The Extracellular Matrix in Pancreatic Cancer: Description of a Complex Network and Promising Therapeutic Options. Cancers (Basel) 2021;13:4442. [PMID: 34503252 DOI: 10.3390/cancers13174442] [Reference Citation Analysis]
45 Chang SC, Hsu CP, Tsai CY, Liu YY, Liu KH, Hsu JT, Yeh TS, Yeh CN, Hwang TL. Selective reoperation after primary resection as a feasible and safe treatment strategy for recurrent pancreatic cancer. Medicine (Baltimore) 2016;95:e4191. [PMID: 27472688 DOI: 10.1097/MD.0000000000004191] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Sahora K, Schindl M, Gnant M. 4th Austrian pancreas day: a summary of the surgical management of exocrine pancreatic neoplasms. Eur Surg 2013;45:277-81. [DOI: 10.1007/s10353-013-0229-5] [Reference Citation Analysis]
47 Hashimoto D, Chikamoto A, Taki K, Arima K, Yamashita Y, Ohmuraya M, Hirota M, Baba H. Residual total pancreatectomy: Short- and long-term outcomes. Pancreatology 2016;16:646-51. [DOI: 10.1016/j.pan.2016.04.034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
48 Ryan JF, Groot VP, Rosati LM, Hacker-Prietz A, Narang AK, McNutt TR, Jackson JF, Le DT, Jaffee EM, Zheng L, Laheru DA, He J, Pawlik TM, Weiss MJ, Wolfgang CL, Herman JM. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. Ann Surg Oncol 2018;25:280-9. [PMID: 29063299 DOI: 10.1245/s10434-017-6134-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
49 Shimoike N, Fujikawa T, Maekawa H, Tanaka A. Aggressive secondary surgery for local recurrence of pancreatic cancer. BMJ Case Rep. 2013;2013. [PMID: 23774708 DOI: 10.1136/bcr-2013-009914] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
50 Munhenzva IR, Barth CW, Sibrian-Vazquez M, Wang LG, Escobedo JO, Gibbs SL, Strongin RM. Assessment of human pancreas cancer tissue and precursor lesions via a fluorophore with inherent PDAC selectivity. Methods 2019;168:35-9. [PMID: 31185273 DOI: 10.1016/j.ymeth.2019.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 Matsuki R, Sugiyama M, Takei H, Kondo H, Fujiwara M, Shibahara J, Furuse J. Long-term survival with repeat resection for lung oligometastasis from pancreatic ductal adenocarcinoma: a case report. Surg Case Rep 2018;4:26. [PMID: 29589221 DOI: 10.1186/s40792-018-0435-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
52 Nakamura A, Itasaka S, Takaori K, Kawaguchi Y, Shibuya K, Yoshimura M, Matsuo Y, Mizowaki T, Uemoto S, Hiraoka M. Radiotherapy for patients with isolated local recurrence of primary resected pancreatic cancer. Prolonged disease-free interval associated with favorable prognosis. Strahlenther Onkol 2014;190:485-90. [PMID: 24599344 DOI: 10.1007/s00066-014-0610-8] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
53 Nordby T, Hugenschmidt H, Fagerland MW, Ikdahl T, Buanes T, Labori KJ. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival. Eur J Surg Oncol. 2013;39:559-566. [PMID: 23498362 DOI: 10.1016/j.ejso.2013.02.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
54 Comito T, Cozzi L, Zerbi A, Franzese C, Clerici E, Tozzi A, Iftode C, Navarria P, D'agostino G, Fogliata A, Mancosu P, Tomatis S, Carnaghi C, Personeni N, Santoro A, Scorsetti M. Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study. European Journal of Surgical Oncology (EJSO) 2017;43:735-42. [DOI: 10.1016/j.ejso.2016.12.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 3.4] [Reference Citation Analysis]
55 Takahashi Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, Nimura Y, Nagino M. Surgery for Recurrent Biliary Tract Cancer: A Single-center Experience With 74 Consecutive Resections. Ann Surg. 2015;262:121-129. [PMID: 25405563 DOI: 10.1097/sla.0000000000000827] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 6.1] [Reference Citation Analysis]
56 Wang C, Li X, Zhang L, Chen Y, Dong R, Zhang J, Zhao J, Guo X, Yang G, Li Y, Gu C, Xi Q, Zhang R. miR-194-5p down-regulates tumor cell PD-L1 expression and promotes anti-tumor immunity in pancreatic cancer. Int Immunopharmacol 2021;97:107822. [PMID: 34098485 DOI: 10.1016/j.intimp.2021.107822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Hashimoto D, Arima K, Nakagawa S, Negoro Y, Hirata T, Hirota M, Inomata M, Fukuzawa K, Ohga T, Saeki H, Oki E, Yamashita YI, Chikamoto A, Baba H, Maehara Y. Pancreatic cancer arising from the remnant pancreas after pancreatectomy: a multicenter retrospective study by the Kyushu Study Group of Clinical Cancer. J Gastroenterol 2019;54:437-48. [PMID: 30515563 DOI: 10.1007/s00535-018-01535-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
58 Tao J, Yang G, Zhou W, Qiu J, Chen G, Luo W, Zhao F, You L, Zheng L, Zhang T, Zhao Y. Targeting hypoxic tumor microenvironment in pancreatic cancer. J Hematol Oncol 2021;14:14. [PMID: 33436044 DOI: 10.1186/s13045-020-01030-w] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
59 Hackert T, Büchler MW, Werner J. Surgical management of pancreatic cancer – standard and extended resections. Eur Surg 2009;41:293-9. [DOI: 10.1007/s10353-009-0498-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
60 O'Leary MP, Choi AH, Kim SI, Chaurasiya S, Lu J, Park AK, Woo Y, Warner SG, Fong Y, Chen NG. Novel oncolytic chimeric orthopoxvirus causes regression of pancreatic cancer xenografts and exhibits abscopal effect at a single low dose. J Transl Med 2018;16:110. [PMID: 29699566 DOI: 10.1186/s12967-018-1483-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
61 Paiella S, Salvia R, Ramera M, Girelli R, Frigerio I, Giardino A, Allegrini V, Bassi C. Local Ablative Strategies for Ductal Pancreatic Cancer (Radiofrequency Ablation, Irreversible Electroporation): A Review. Gastroenterol Res Pract. 2016;2016:4508376. [PMID: 26981115 DOI: 10.1155/2016/4508376] [Cited by in Crossref: 40] [Cited by in F6Publishing: 30] [Article Influence: 6.7] [Reference Citation Analysis]
62 Thomas RM, Truty MJ, Nogueras-Gonzalez GM, Fleming JB, Vauthey JN, Pisters PW, Lee JE, Rice DC, Hofstetter WL, Wolff RA. Selective reoperation for locally recurrent or metastatic pancreatic ductal adenocarcinoma following primary pancreatic resection. J Gastrointest Surg. 2012;16:1696-1704. [PMID: 22644446 DOI: 10.1007/s11605-012-1912-8] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 7.2] [Reference Citation Analysis]
63 Chang A, Kim-Fuchs C, Le CP, Hollande F, Sloan EK. Neural Regulation of Pancreatic Cancer: A Novel Target for Intervention. Cancers (Basel) 2015;7:1292-312. [PMID: 26193320 DOI: 10.3390/cancers7030838] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
64 Sheffield KM, Crowell KT, Lin YL, Djukom C, Goodwin JS, Riall TS. Surveillance of pancreatic cancer patients after surgical resection. Ann Surg Oncol 2012;19:1670-7. [PMID: 22143577 DOI: 10.1245/s10434-011-2152-y] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
65 Kim HR, Seo M, Nah YW, Park HW, Park SH. Clinical impact of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in patients with resectable pancreatic cancer: diagnosing lymph node metastasis and predicting survival. Nucl Med Commun 2018;39:691-8. [PMID: 29893751 DOI: 10.1097/MNM.0000000000000855] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
66 Hüser N, Michalski CW, Schuster T, Friess H, Kleeff J. Systematic review and meta-analysis of prophylactic gastroenterostomy for unresectable advanced pancreatic cancer. Br J Surg. 2009;96:711-719. [PMID: 19526616 DOI: 10.1002/bjs.6629] [Cited by in Crossref: 39] [Cited by in F6Publishing: 25] [Article Influence: 3.0] [Reference Citation Analysis]
67 Lavu H, Nowcid LJ, Klinge MJ, Mahendraraj K, Grenda DR, Sauter PK, Rosato EL, Kennedy EP, Yeo CJ. Reoperative completion pancreatectomy for suspected malignant disease of the pancreas. J Surg Res. 2011;170:89-95. [PMID: 21696765 DOI: 10.1016/j.jss.2011.04.050] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
68 Kyaw PPP, Goh BKP. Robotic assisted laparoscopic completion pancreatectomy for recurrent intraductal papillary mucinous neoplasm after previous open pancreatoduodenectomy: A case report and literature review. Ann Hepatobiliary Pancreat Surg 2019;23:206-9. [PMID: 31225427 DOI: 10.14701/ahbps.2019.23.2.206] [Reference Citation Analysis]
69 Ogino T, Ueda J, Sato N, Takahata S, Mizumoto K, Nakamura M, Oda Y, Tanaka M. Repeated Pancreatectomy for Recurrent Pancreatic Carcinoma after Pylorus-Preserving Pancreatoduodenectomy: Report of Two Patients. Case Rep Gastroenterol. 2010;4:429-434. [PMID: 21060713 DOI: 10.1159/000321513] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
70 Kim YI, Song KB, Lee YJ, Park KM, Hwang DW, Lee JH, Shin SH, Kwon JW, Ro JS, Kim SC. Management of isolated recurrence after surgery for pancreatic adenocarcinoma. Br J Surg 2019;106:898-909. [PMID: 31162655 DOI: 10.1002/bjs.11144] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
71 Gong Y, Qian Y, Luo G, Liu Y, Wang R, Deng S, Cheng H, Jin K, Ni Q, Yu X, Wu W, Liu C. High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma. World J Surg Oncol 2021;19:35. [PMID: 33517899 DOI: 10.1186/s12957-021-02147-z] [Reference Citation Analysis]
72 Grapa CM, Mocan L, Crisan D, Florea M, Mocan T. Biomarkers in Pancreatic Cancer as Analytic Targets for Nanomediated Imaging and Therapy. Materials (Basel) 2021;14:3083. [PMID: 34199998 DOI: 10.3390/ma14113083] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
73 Kitano Y, Yamashita Y, Nakagawa S, Okabe H, Imai K, Chikamoto A, Baba H. Effectiveness of surgery for recurrent cholangiocarcinoma: A single center experience and brief literature review. The American Journal of Surgery 2020;219:175-80. [DOI: 10.1016/j.amjsurg.2019.02.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
74 Hackert T, Büchler MW, Werner J. Current state of surgical management of pancreatic cancer. Cancers (Basel). 2011;3:1253-1273. [PMID: 24212660 DOI: 10.3390/cancers3011253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
75 Miyagawa Y, Kitazawa M, Kitahara H, Karasawa Y, Orii T, Soejima Y. Three Curative Pancreatectomies for the Metachronous Appearance of Pancreatic Invasive Ductal Adenocarcinoma. Case Rep Oncol 2020;13:392-7. [PMID: 32355495 DOI: 10.1159/000506732] [Reference Citation Analysis]
76 Shonaka T, Inagaki M, Akabane H, Yanagida N, Shomura H, Yanagawa N, Oikawa K, Nakano S. Total pancreatectomy for metachronous mixed acinar-ductal carcinoma in a remnant pancreas. World J Gastroenterol 2014; 20(33): 11904-11909 [PMID: 25206298 DOI: 10.3748/wjg.v20.i33.11904] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
77 Yamada D, Eguchi H, Iwagami Y, Asaoka T, Noda T, Kawamoto K, Gotoh K, Kobayashi S, Mori M, Doki Y. The investigation of the survival time after recurrence in patients with pancreatic ductal adenocarcinoma for individualization of adjuvant chemotherapy. Surg Today 2018;48:952-62. [PMID: 29770847 DOI: 10.1007/s00595-018-1674-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
78 Hardacre JM. Completion Pancreaticoduodenectomy for a Second Primary Pancreatic Cancer: A Case Report. Case Rep Pancreat Cancer 2016;2:50-2. [PMID: 30631816 DOI: 10.1089/crpc.2016.0010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
79 Aquilani R, Brugnatelli S, Maestri R, Boschi F, Filippi B, Perrone L, Barbieri A, Buonocore D, Dossena M, Verri M. Peripheral Blood Lymphocyte Percentage May Predict Chemotolerance and Survival in Patients with Advanced Pancreatic Cancer. Association between Adaptive Immunity and Nutritional State. Curr Oncol 2021;28:3280-96. [PMID: 34449579 DOI: 10.3390/curroncol28050285] [Reference Citation Analysis]
80 Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H, Schirmacher P, Büchler MW. Most pancreatic cancer resections are R1 resections. Ann Surg Oncol. 2008;15:1651-1660. [PMID: 18351300 DOI: 10.1245/s10434-008-9839-8] [Cited by in Crossref: 426] [Cited by in F6Publishing: 376] [Article Influence: 30.4] [Reference Citation Analysis]
81 Sunagawa H, Mayama Y, Orokawa T, Oshiro N. Laparoscopic total remnant pancreatectomy after laparoscopic pancreaticoduodenectomy: Laparoscopic remnant pancreatectomy. Asian J Endosc Surg 2014;7:71-4. [DOI: 10.1111/ases.12064] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
82 Navarro S, Vaquero E, Maurel J, Bombí JA, De Juan C, Feliu J, Fernández Cruz L, Ginés A, Girela E, Rodríguez R, Sabater L; en representación del Grupo Español de Consenso en Cáncer de Páncreas., el Club Español Biliopancreático (CEBP)., Grupo Español Multidisciplinar de Cáncer Digestivo (GEMCAD)., Sociedad Española de Diagnóstico por Imagen del Abdomen (SEDIA)., Sociedad Española de Endoscopia Digestiva (SEED)., la Sociedad Española de Anatomía Patológica (SEAP). [Recommendations for diagnosis, staging and treatment of pancreatic cancer (Part II)]. Med Clin (Barc) 2010;134:692-702. [PMID: 20356609 DOI: 10.1016/j.medcli.2010.01.006] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
83 Miyasaka M, Noji T, Ohtaka K, Chiba R, Sato S, Shoji Y, Hase R, Ichimura T, Hirano S, Senmaru N. Long-term survival after repeated resection of metachronous lung metastases from pStage IA pancreatic adenocarcinoma. Clin J Gastroenterol 2018;11:53-61. [DOI: 10.1007/s12328-017-0781-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
84 Vining CC, Skowron KB, Hogg ME. Robotic gastrointestinal surgery: learning curve, educational programs and outcomes. Updates Surg 2021;73:799-814. [PMID: 33484423 DOI: 10.1007/s13304-021-00973-0] [Reference Citation Analysis]
85 Gamboa AC, Zaidi MY, Lee RM, Sarmiento JM, Kooby DA, Russell MC, Cardona K, Maithel SK. The Path to Whipple Reconstruction for Pancreatic Adenocarcinoma: Trans-Mesocolon or Through Ligament of Treitz? J Gastrointest Surg 2020;24:2046-53. [PMID: 31468334 DOI: 10.1007/s11605-019-04377-9] [Reference Citation Analysis]
86 Liu L, Xu H, Wang W, Wu C, Chen Y, Yang J, Cen P, Xu J, Liu C, Long J. A preoperative serum signature of CEA+/CA125+/CA19-9 ≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer. 2015;136:2216-2227. [PMID: 25273947 DOI: 10.1002/ijc.29242] [Cited by in Crossref: 44] [Cited by in F6Publishing: 56] [Article Influence: 5.5] [Reference Citation Analysis]
87 Ilmer M, Schiergens TS, Renz BW, Schneider C, Sargut M, Waligora R, Weniger M, Hartwig W, Ceyhan GO, Friess H, Werner J, D'Haese JG. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Surg Oncol 2019;31:16-21. [PMID: 31473583 DOI: 10.1016/j.suronc.2019.08.010] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
88 Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267. [PMID: 20422030 DOI: 10.1371/journal.pmed.1000267] [Cited by in Crossref: 923] [Cited by in F6Publishing: 846] [Article Influence: 76.9] [Reference Citation Analysis]
89 Allaway RJ, Fischer DA, de Abreu FB, Gardner TB, Gordon SR, Barth RJ, Colacchio TA, Wood M, Kacsoh BZ, Bouley SJ, Cui J, Hamilton J, Choi JA, Lange JT, Peterson JD, Padmanabhan V, Tomlinson CR, Tsongalis GJ, Suriawinata AA, Greene CS, Sanchez Y, Smith KD. Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget. 2016;7:17087-17102. [PMID: 26934555 DOI: 10.18632/oncotarget.7718] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
90 Meng H, Zhao Y, Dong J, Xue M, Lin YS, Ji Z, Mai WX, Zhang H, Chang CH, Brinker CJ, Zink JI, Nel AE. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice. ACS Nano 2013;7:10048-65. [PMID: 24143858 DOI: 10.1021/nn404083m] [Cited by in Crossref: 110] [Cited by in F6Publishing: 103] [Article Influence: 12.2] [Reference Citation Analysis]
91 Byrne JD, Jajja MR, Schorzman AN, Keeler AW, Luft JC, Zamboni WC, DeSimone JM, Yeh JJ. Iontophoretic device delivery for the localized treatment of pancreatic ductal adenocarcinoma. Proc Natl Acad Sci U S A 2016;113:2200-5. [PMID: 26858448 DOI: 10.1073/pnas.1600421113] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
92 Kitajima K, Murakami K, Yamasaki E, Kaji Y, Shimoda M, Kubota K, Suganuma N, Sugimura K. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent pancreatic cancer: comparison with integrated FDG-PET/non-contrast-enhanced CT and enhanced CT. Mol Imaging Biol. 2010;12:452-459. [PMID: 19949988 DOI: 10.1007/s11307-009-0271-7] [Cited by in Crossref: 46] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
93 Mizumoto T, Terashima K, Matsuo Y, Nagano F, Demizu Y, Mima M, Sulaiman NS, Tokumaru S, Okimoto T, Toyama H, Fukumoto T. Proton Radiotherapy for Isolated Local Recurrence of Primary Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 2019;26:2587-94. [PMID: 31147994 DOI: 10.1245/s10434-019-07471-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
94 Suzuki S, Shimoda M, Shimazaki J, Maruyama T, Nishida K. Clinical Outcome of Resected Remnant Pancreatic Cancer After Resection of the Primary Pancreatic Cancer. J Invest Surg 2019;32:670-8. [PMID: 29589962 DOI: 10.1080/08941939.2018.1452995] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
95 Doi C, Egashira N, Kawabata A, Maurya DK, Ohta N, Uppalapati D, Ayuzawa R, Pickel L, Isayama Y, Troyer D, Takekoshi S, Tamura M. Angiotensin II type 2 receptor signaling significantly attenuates growth of murine pancreatic carcinoma grafts in syngeneic mice. BMC Cancer 2010;10:67. [PMID: 20181281 DOI: 10.1186/1471-2407-10-67] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 4.0] [Reference Citation Analysis]
96 Torres C, Grippo PJ. Pancreatic cancer subtypes: a roadmap for precision medicine. Ann Med 2018;50:277-87. [PMID: 29537309 DOI: 10.1080/07853890.2018.1453168] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
97 Zhu X, Cao Y, Liu W, Ju X, Zhao X, Jiang L, Ye Y, Jin G, Zhang H. Stereotactic body radiotherapy plus pembrolizumab and trametinib versus stereotactic body radiotherapy plus gemcitabine for locally recurrent pancreatic cancer after surgical resection: an open-label, randomised, controlled, phase 2 trial. Lancet Oncol 2021;22:1093-102. [PMID: 34237249 DOI: 10.1016/S1470-2045(21)00286-2] [Reference Citation Analysis]
98 Weyhe D, Obonyo D, Uslar VN, Stricker I, Tannapfel A. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data. PLoS One 2021;16:e0248633. [PMID: 33735191 DOI: 10.1371/journal.pone.0248633] [Reference Citation Analysis]
99 Umezaki N, Hashimoto D, Nakagawa S, Yamao T, Tsukamoto M, Kitano Y, Arima K, Yamamura K, Miyata T, Okabe H, Chikamoto A, Matsumura F, Baba H. Cystic gastric metastasis from pancreatic cancer.Surg Case Rep. 2018;4:31. [PMID: 29633044 DOI: 10.1186/s40792-018-0443-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
100 Wild AT, Hiniker SM, Chang DT, Tran PT, Khashab MA, Limaye MR, Laheru DA, Le DT, Kumar R, Pai JS. Re-irradiation with stereotactic body radiation therapy as a novel treatment option for isolated local recurrence of pancreatic cancer after multimodality therapy: experience from two institutions. J Gastrointest Oncol. 2013;4:343-351. [PMID: 24294505 DOI: 10.3978/j.issn.2078-6891.2013.044] [Cited by in F6Publishing: 20] [Reference Citation Analysis]
101 Kang CM, Lee WJ. Is Laparoscopic Pancreaticoduodenectomy Feasible for Pancreatic Ductal Adenocarcinoma? Cancers (Basel) 2020;12:E3430. [PMID: 33218187 DOI: 10.3390/cancers12113430] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
102 Thapa RK, Nguyen HT, Gautam M, Shrestha A, Lee ES, Ku SK, Choi HG, Yong CS, Kim JO. Hydrophobic binding peptide-conjugated hybrid lipid-mesoporous silica nanoparticles for effective chemo-photothermal therapy of pancreatic cancer. Drug Deliv 2017;24:1690-702. [PMID: 29098877 DOI: 10.1080/10717544.2017.1396382] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 4.8] [Reference Citation Analysis]
103 Loos M, Kleeff J, Friess H, Büchler MW. Approaches to localized pancreatic cancer. Curr Oncol Rep 2008;10:212-9. [DOI: 10.1007/s11912-008-0033-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
104 Kersting S, Janot MS, Chromik AM, Suelberg D, Uhl W, Seelig MH. Contemporary Single-Center Surgical Experiences in Redo Procedures of the Pancreas: Improved Outcome and Reduction of Operative Risk. J Gastrointest Surg 2011;15:191-8. [DOI: 10.1007/s11605-010-1384-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
105 Deobald RG, Cheng ES, Ko YJ, Wright FC, Karanicolas PJ. A qualitative study of patient and clinician attitudes regarding surveillance after a resection of pancreatic and peri-ampullary cancer. HPB (Oxford) 2015;17:409-15. [PMID: 25545219 DOI: 10.1111/hpb.12378] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
106 Fujisaki S, Takashina M, Tomita R, Sakurai K, Takayama T. Long-term survival following hepatectomy, radiation, and chemotherapy for recurrent pancreatic carcinoma: a case report. World J Surg Oncol 2017;15:157. [PMID: 28835248 DOI: 10.1186/s12957-017-1232-2] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
107 Kyriazanos ID, Tsoukalos GG, Papageorgiou G, Verigos KE, Miliadis L, Stoidis CN. Local recurrence of pancreatic cancer after primary surgical intervention: how to deal with this devastating scenario? Surg Oncol 2011;20:e133-42. [PMID: 21576013 DOI: 10.1016/j.suronc.2011.04.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
108 Boimel PJ, Berman AT, Li J, Apisarnthanarax S, Both S, Lelionis K, Larson GL, Teitelbaum U, Lukens JN, Ben-Josef E, Metz JM, Plastaras JP. Proton beam reirradiation for locally recurrent pancreatic adenocarcinoma. J Gastrointest Oncol 2017;8:665-74. [PMID: 28890817 DOI: 10.21037/jgo.2017.03.04] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
109 Bhandare MS, Mondal A, Chaudhari V, Bal M, Yadav S, Ramaswamy A, Ostwal V, Shetty N, Shrikhande SV. Factors influencing local and distant recurrence following resection of periampullary cancer. Br J Surg 2021;108:427-34. [PMID: 33723577 DOI: 10.1093/bjs/znaa143] [Reference Citation Analysis]
110 Kruger S, Haas M, Burger PJ, Ormanns S, Modest DP, Westphalen CB, Michl M, Kleespies A, Angele MK, Hartwig W, Bruns CJ, Niyazi M, Roeder F, Kirchner T, Werner J, Heinemann V, Boeck S. Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology 2016;16:593-8. [PMID: 27067420 DOI: 10.1016/j.pan.2016.03.016] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
111 Cao Z, Xu J, Shao Q, Zhang T, Zhao Y. Surgical treatment of pancreatic head cancer: concept revolutions and arguments. Chin J Cancer Res. 2015;27:392-396. [PMID: 26361408 DOI: 10.3978/j.issn.1000-9604.2015.04.13] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
112 Elmi A, Murphy J, Hedgire S, Mcdermott S, Abtahi S, Halpern E, Fernandez-del Castillo C, Harisinghani M. Post-Whipple imaging in patients with pancreatic ductal adenocarcinoma: association with overall survival: a multivariate analysis. Abdom Radiol 2017;42:2101-7. [DOI: 10.1007/s00261-017-1099-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
113 Meng H, Wei R. Use of smart designed nanoparticles to impact cancer surgery. Science Bulletin 2015;60:142-3. [DOI: 10.1007/s11434-014-0701-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
114 Sutera PA, Bernard ME, Wang H, Heron DE. Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma. Front Oncol 2018;8:282. [PMID: 30101127 DOI: 10.3389/fonc.2018.00282] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
115 Klose J, Ronellenfitsch U, Kleeff J. Management problems in patients with pancreatic cancer from a surgeon's perspective. Semin Oncol 2021:S0093-7754(21)00014-2. [PMID: 34059343 DOI: 10.1053/j.seminoncol.2021.02.008] [Reference Citation Analysis]
116 Hamner JB, White M, Crowder C, Singh G. Resection of metachronous pancreatic cancer 4 years after pancreaticoduodenectomy for stage III pancreatic adenocarcinoma. World J Surg Oncol 2015;13:290. [PMID: 26419361 DOI: 10.1186/s12957-015-0712-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
117 Kim-Fuchs C, Le CP, Pimentel MA, Shackleford D, Ferrari D, Angst E, Hollande F, Sloan EK. Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behav Immun 2014;40:40-7. [PMID: 24650449 DOI: 10.1016/j.bbi.2014.02.019] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 13.3] [Reference Citation Analysis]
118 Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466-473. [PMID: 21878232 DOI: 10.1016/j.surg.2011.07.006] [Cited by in Crossref: 138] [Cited by in F6Publishing: 122] [Article Influence: 12.5] [Reference Citation Analysis]
119 Wang XY, Yang F, Jin C, Fu DL. Utility of PET/CT in diagnosis, staging, assessment of resectability and metabolic response of pancreatic cancer. World J Gastroenterol 2014; 20(42): 15580-15589 [PMID: 25400441 DOI: 10.3748/wjg.v20.i42.15580] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 28] [Article Influence: 5.0] [Reference Citation Analysis]
120 Simon PO Jr, McDunn JE, Kashiwagi H, Chang K, Goedegebuure PS, Hotchkiss RS, Hawkins WG. Targeting AKT with the proapoptotic peptide, TAT-CTMP: a novel strategy for the treatment of human pancreatic adenocarcinoma. Int J Cancer 2009;125:942-51. [PMID: 19405118 DOI: 10.1002/ijc.24424] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
121 Sahakyan MA, Yaqub S, Kazaryan AM, Villanger O, Berstad AE, Labori KJ, Edwin B, Røsok BI. Laparoscopic Completion Pancreatectomy for Local Recurrence in the Pancreatic Remnant after Pancreaticoduodenectomy: Case Reports and Review of the Literature. J Gastrointest Cancer 2016;47:509-13. [PMID: 26732389 DOI: 10.1007/s12029-015-9796-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
122 Park SJ, Kim SM, Moon JH, Kim JH, Shin JS, Hong SW, Shin YJ, Lee DH, Lee EY, Hwang IY, Kim JE, Kim KP, Hong YS, Lee WK, Choi EK, Lee JS, Jin DH, Kim TW. SAHA, an HDAC inhibitor, overcomes erlotinib resistance in human pancreatic cancer cells by modulating E-cadherin. Tumour Biol 2016;37:4323-30. [PMID: 26493999 DOI: 10.1007/s13277-015-4216-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
123 Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D, Saida L, Suker M, van der Harst E, Mieog JS, Bonsing BA, Klaver Y, Koerkamp BG, van Eijck CH. The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective Multicenter Cohort Study. Ann Surg 2019;270:139-46. [PMID: 29334554 DOI: 10.1097/SLA.0000000000002660] [Cited by in Crossref: 76] [Cited by in F6Publishing: 57] [Article Influence: 38.0] [Reference Citation Analysis]
124 Blakely K, Karanicolas PJ, Wright FC, Gotlib Conn L. Optimistic honesty: understanding surgeon and patient perspectives on hopeful communication in pancreatic cancer care. HPB (Oxford) 2017;19:611-9. [PMID: 28528268 DOI: 10.1016/j.hpb.2017.04.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
125 Koom WS, Mori S, Furuich W, Yamada S. Beam direction arrangement using a superconducting rotating gantry in carbon ion treatment for pancreatic cancer. Br J Radiol 2019;92:20190101. [PMID: 30943057 DOI: 10.1259/bjr.20190101] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
126 Groot VP, van Santvoort HC, Rombouts SJ, Hagendoorn J, Borel Rinkes IH, van Vulpen M, Herman JM, Wolfgang CL, Besselink MG, Molenaar IQ. Systematic review on the treatment of isolated local recurrence of pancreatic cancer after surgery; re-resection, chemoradiotherapy and SBRT. HPB 2017;19:83-92. [DOI: 10.1016/j.hpb.2016.11.001] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 7.8] [Reference Citation Analysis]
127 Kim HS, Park JS, Lim JH, Back JH, Yoon DS. Surgical management of malignant bowel obstruction in recurrent pancreatic cancer. Int J Surg Case Rep 2017;32:40-2. [PMID: 28219849 DOI: 10.1016/j.ijscr.2017.01.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
128 Blazer M, Wu C, Goldberg RM, Phillips G, Schmidt C, Muscarella P, Wuthrick E, Williams TM, Reardon J, Ellison EC, Bloomston M, Bekaii-Saab T. Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol. 2015;22:1153-1159. [PMID: 25358667 DOI: 10.1245/s10434-014-4225-1] [Cited by in Crossref: 158] [Cited by in F6Publishing: 134] [Article Influence: 19.8] [Reference Citation Analysis]
129 Zettlitz KA, Tsai WK, Knowles SM, Kobayashi N, Donahue TR, Reiter RE, Wu AM. Dual-Modality Immuno-PET and Near-Infrared Fluorescence Imaging of Pancreatic Cancer Using an Anti-Prostate Stem Cell Antigen Cys-Diabody. J Nucl Med 2018;59:1398-405. [PMID: 29602820 DOI: 10.2967/jnumed.117.207332] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
130 Miyazaki Y, Kokudo T, Amikura K, Kageyama Y, Takahashi A, Ohkohchi N, Sakamoto H. Survival of surgery for recurrent biliary tract cancer: a single-center experience and systematic review of literature. Japanese Journal of Clinical Oncology 2017;47:206-12. [DOI: 10.1093/jjco/hyw182] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
131 Nieß H, Kleespies A, Andrassy J, Pratschke S, Angele MK, Guba M, Jauch KW, Bruns CJ. [Pancreatic cancer in the elderly: guidelines and individualized therapy]. Chirurg 2013;84:291-5. [PMID: 23479275 DOI: 10.1007/s00104-012-2455-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
132 Michalski CW, Weitz J, Büchler MW. Surgery insight: surgical management of pancreatic cancer. Nat Clin Pract Oncol. 2007;4:526-535. [PMID: 17728711 DOI: 10.1038/ncponc0925] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 3.0] [Reference Citation Analysis]
133 Gangl O, Fröschl U, Dutta-függer B, Függer R. Elective pancreatic reresection – report of a series and review of the literature. Eur Surg 2010;42:91-5. [DOI: 10.1007/s10353-010-0527-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
134 Hashimoto D, Chikamoto A, Masuda T, Nakagawa S, Imai K, Yamashita YI, Reber HA, Baba H. Pancreatic Cancer Arising From the Remnant Pancreas: Is It a Local Recurrence or New Primary Lesion? Pancreas 2017;46:1083-90. [PMID: 28902776 DOI: 10.1097/MPA.0000000000000897] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
135 Suzuki S, Furukawa T, Oshima N, Izumo W, Shimizu K, Yamamoto M. Original Scientific Reports: Clinicopathological Findings of Remnant Pancreatic Cancers in Survivors Following Curative Resections of Pancreatic Cancers. World J Surg 2016;40:974-81. [PMID: 26589594 DOI: 10.1007/s00268-015-3353-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
136 Welsch T, Keleg S, Bergmann F, Degrate L, Bauer S, Schmidt J. Comparative analysis of tumorbiology and CD133 positivity in primary and recurrent pancreatic ductal adenocarcinoma. Clin Exp Metastasis 2009;26:701-11. [PMID: 19488831 DOI: 10.1007/s10585-009-9269-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
137 Motoyama H, Kobayashi A, Yokoyama T, Shimizu A, Kitagawa N, Notake T, Fukushima K, Masuo H, Yoshizawa T, Miyagawa S. Survival Benefits of Surgical Resection in Patients with Recurrent Biliary Tract Carcinoma. World J Surg 2017;41:2817-29. [DOI: 10.1007/s00268-017-4107-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
138 Frei L, Stieger R, Bayerl C, Breitenstein S, Staerkle RF. Resectable adenocarcinoma developing in the remnant pancreas 7 years after partial pancreatoduodenectomy for invasive ductal adenocarcinoma of the pancreas: a case report. J Med Case Rep 2017;11:194. [PMID: 28716115 DOI: 10.1186/s13256-017-1359-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
139 Moletta L, Serafini S, Valmasoni M, Pierobon ES, Ponzoni A, Sperti C. Surgery for Recurrent Pancreatic Cancer: Is It Effective? Cancers (Basel) 2019;11:E991. [PMID: 31315222 DOI: 10.3390/cancers11070991] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
140 Słotwiński R, Lech G, Słotwińska SM. Molecular aspects of pancreatic cancer: focus on reprogrammed metabolism in a nutrient-deficient environment and potential therapeutic targets. Cent Eur J Immunol 2021;46:258-63. [PMID: 34764796 DOI: 10.5114/ceji.2021.107027] [Reference Citation Analysis]
141 Strobel O, Hartwig W, Hackert T, Hinz U, Berens V, Grenacher L, Bergmann F, Debus J, Jäger D, Büchler M. Re-resection for isolated local recurrence of pancreatic cancer is feasible, safe, and associated with encouraging survival. Ann Surg Oncol. 2013;20:964-972. [PMID: 23233235 DOI: 10.1245/s10434-012-2762-z] [Cited by in Crossref: 79] [Cited by in F6Publishing: 73] [Article Influence: 7.9] [Reference Citation Analysis]
142 Rosumeck N, Timmermann L, Klein F, Bahra M, Stintzig S, Malinka T, Pelzer U. Induction Chemotherapy for Primarily Unresectable Locally Advanced Pancreatic Adenocarcinoma-Who Will Benefit from a Secondary Resection? Medicina (Kaunas) 2021;57:77. [PMID: 33477505 DOI: 10.3390/medicina57010077] [Reference Citation Analysis]
143 Kim HS, Nakagawa K, Akahori T, Nakamura K, Takagi T, Sho M, Park JS, Yoon DS. Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma? J Clin Med 2021;10:873. [PMID: 33672686 DOI: 10.3390/jcm10040873] [Reference Citation Analysis]
144 Poruk KE, Blackford AL, Weiss MJ, Cameron JL, He J, Goggins M, Rasheed ZA, Wolfgang CL, Wood LD. Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res 2017;23:2681-90. [PMID: 27789528 DOI: 10.1158/1078-0432.CCR-16-1467] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 7.8] [Reference Citation Analysis]
145 Sperti C, Pasquali C, Bissoli S, Chierichetti F, Liessi G, Pedrazzoli S. Tumor relapse after pancreatic cancer resection is detected earlier by 18-FDG PET than by CT. J Gastrointest Surg. 2010;14:131-140. [PMID: 19777315 DOI: 10.1007/s11605-009-1010-8] [Cited by in Crossref: 58] [Cited by in F6Publishing: 43] [Article Influence: 4.5] [Reference Citation Analysis]
146 Takano S, Yoshitomi H, Kagawa S, Furukawa K, Takayashiki T, Kuboki S, Suzuki D, Sakai N, Mishima T, Nakadai E, Miyazaki M, Ohtsuka M. Long-term outcomes and significance of preoperative lymphocyte-to-monocyte ratio as a prognostic indicator in patients with invasive pancreatic neoplasms after repeat pancreatectomy. BMC Cancer 2020;20:111. [PMID: 32041563 DOI: 10.1186/s12885-020-6602-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
147 Ferino A, Miglietta G, Picco R, Vogel S, Wengel J, Xodo LE. MicroRNA therapeutics: design of single-stranded miR-216b mimics to target KRAS in pancreatic cancer cells. RNA Biol 2018;15:1273-85. [PMID: 30306823 DOI: 10.1080/15476286.2018.1526536] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
148 Boone BA, Zeh HJ, Mock BK, Johnson PJ, Dvorchik I, Lee K, Moser AJ, Bartlett DL, Marsh JW. Resection of isolated local and metastatic recurrence in periampullary adenocarcinoma. HPB (Oxford). 2014;16:197-203. [PMID: 23601033 DOI: 10.1111/hpb.12119] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
149 Li J, Wang Z, Li AM, Zhou H, Zhu XX. Analysis of the efficacy, safety and survival factors of stereotactic body radiation therapy in patients with recurrence of pancreatic cancer. Transl Oncol 2020;13:100818. [PMID: 32592902 DOI: 10.1016/j.tranon.2020.100818] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
150 Shinoto M, Ebner DK, Yamada S. Particle Radiation Therapy for Gastrointestinal Cancers. Curr Oncol Rep 2016;18:17. [PMID: 26849660 DOI: 10.1007/s11912-016-0499-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
151 Volk A, Distler M, Müssle B, Berning M, Hampe J, Brückner S, Weitz J, Welsch T. Reproducibility of preoperative endoscopic injection of botulinum toxin into the sphincter of Oddi to prevent postoperative pancreatic fistula. Innov Surg Sci 2018;3:69-75. [PMID: 31579768 DOI: 10.1515/iss-2017-0040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
152 Tsilimigras DI, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A, Aldrighetti L, Weiss M, Bauer TW, Alexandrescu S, Poultsides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp BG, Moro A, Sasaki K, Aucejo F, Zhang XF, Matsuyama R, Endo I, Pawlik TM. Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches. JAMA Surg 2020;155:823-31. [PMID: 32639548 DOI: 10.1001/jamasurg.2020.1973] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 22.0] [Reference Citation Analysis]